IP Library › Granted Patent US 7,105,011
Granted Patent B2
US 7,105,011 · App. 10/414,781 · Granted Sep 12, 2006

Method for achieving tissue changes in bone or bone-derived tissue

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,105,011
App. No.
10/414,781
Granted
Sep 12, 2006
Kind
B2
Abstract

A method of achieving tissue changes in bone or bone-derived organic tissue, in which method bone or bone-derived organic tissue is provided, an interfacing agent is applied to the bone or bone-derived organic tissue, and electromagnetic energy is applied to the interfacing agent. The interfacing agent can include collagen, preferably bone-derived collagen, and a therapeutic agent. In a related embodiment, a method of treating bone tissue is provided wherein a bioactive interfacing agent is placed between the bone segments of the bone tissue to be treated.

Claims (16)

1. A method of achieving tissue changes in bone or bone-derived organic tissue comprising the steps of:

providing bone or bone-derived organic tissue in an electrically conductive medium;

applying an interfacing agent to the bone or bone-derived organic tissue; and

applying electromagnetic energy to the interfacing agent while the bone or bone-derived organic tissue is in the electrically conductive medium.

2. The method of claim 1 wherein the applying step comprises applying radio frequency energy.

3. The method of claim 1 wherein the interfacing agent comprises collagen and a therapeutic agent.

4. The method of claim 3 , wherein the collagen is bone-derived collagen.

5. The method of claim 4 , wherein the source of bone-derived collagen is acid treated bone-derived graft material.

6. The method of claim 5 , wherein the acid treated bone-derived graft material is derived from autologous bone of the patient to be treated.

7. The method of claim 3 , wherein the collagen is made by synthetic or recombinant means.

8. The method of claim 3 , wherein the therapeutic agent comprises hydroxyapetite.

9. The method of claim 3 , wherein the therapeutic agent comprises an osteogenic protein.

10. The method of claim 3 , wherein the therapeutic agent comprises a growth factor.

11. The method of claim 1 , wherein the interfacing agent comprises one or more members from the group consisting of osteoconductive, osteoinductive, and osteogenic substances or agents.

12. The method of claim 1 , wherein the interfacing agent comprises a hydrophobic, lipophilic carrier paste-gel-like material.

13. The method of claim 1 , wherein the interfacing agent comprises heat releasing microspheres.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2009
From: MAP TECHNOLOGIES LLC
To: NUORTHO SURGICAL, INC.
Reel/Frame 022494/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2006
From: AUGE, WAYNE K., II
To: MAP TECHNOLOGIES LLC
Reel/Frame 018480/0496 →
Continuity (4)
Division 0988574900 · Jun 19, 2001
Provisional Application 6027295500 · Mar 2, 2001
Provisional Application 6022637000 · Aug 18, 2000
Related Publication 20030175251A1 · Sep 18, 2003